menu
    • menu
    [{"orgOrder":0,"company":"McNeil Consumer Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"JNJ-10450232","moa":"A3AR","graph1":"Neurology","graph2":"Phase II","graph3":"McNeil Consumer Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McNeil Consumer Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"McNeil Consumer Health \/ Undisclosed"},{"orgOrder":0,"company":"McNeil Consumer Health","sponsor":"McNeil Consumer Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"McNeil Consumer Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McNeil Consumer Health \/ McNeil Consumer Health","highestDevelopmentStatusID":"11","companyTruncated":"McNeil Consumer Health \/ McNeil Consumer Health"},{"orgOrder":0,"company":"McNeil Consumer Health","sponsor":"GSK | McNeil AB","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"McNeil Consumer Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"McNeil Consumer Health \/ GSK | McNeil AB","highestDevelopmentStatusID":"10","companyTruncated":"McNeil Consumer Health \/ GSK | McNeil AB"},{"orgOrder":0,"company":"McNeil Consumer Health","sponsor":"McNeil AB | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"McNeil Consumer Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McNeil Consumer Health \/ McNeil AB | GSK","highestDevelopmentStatusID":"10","companyTruncated":"McNeil Consumer Health \/ McNeil AB | GSK"},{"orgOrder":0,"company":"McNeil Consumer Health","sponsor":"McNeil Consumer Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"McNeil Consumer Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McNeil Consumer Health \/ McNeil Consumer Health","highestDevelopmentStatusID":"9","companyTruncated":"McNeil Consumer Health \/ McNeil Consumer Health"},{"orgOrder":0,"company":"McNeil Consumer Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"McNeil Consumer Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Tablet","sponsorNew":"McNeil Consumer Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"McNeil Consumer Health \/ Undisclosed"},{"orgOrder":0,"company":"McNeil Consumer Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"McNeil Consumer Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McNeil Consumer Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"McNeil Consumer Health \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by McNeil Consumer Health

    Menu

    McNeil Consumer Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : GSK | McNeil AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy

                            Details : Nicotine is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tobacco Use Disorder.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 04, 2015

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : GSK | McNeil AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II/ Phase III

                            Recipient : University of Utah

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD

                            Details : Methylphenidate is a Controlled Substance drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 13, 2014

                            Lead Product(s) : Methylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : University of Utah

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JNJ-10450232

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine

                            Details : JNJ-10450232 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 05, 2014

                            Lead Product(s) : JNJ-10450232

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Long-Acting Acetaminophen in Postoperative Dental Pain

                            Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Toothache.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 10, 2013

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Recipient : California Allergy and Asthma Medical Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Bronchodilation Effects of Cetirizine

                            Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 01, 2013

                            Lead Product(s) : Cetirizine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Recipient : California Allergy and Asthma Medical Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : McNeil AB | GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking

                            Details : Nicotine is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tobacco Use Disorder.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 15, 2011

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : McNeil AB | GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            McNeil Consumer Health

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery

                            Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 04, 2010

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth